Electra Therapeutics is a speculative biotech with no reported margins and below-average business quality, but insiders bought about $40.0M (7.05% of market cap) in 90 days with no sales, a strong show of conviction. Price data was unavailable this run, so no trade setup exists.
Thesis pillars
- Binary Biotech Speculative Profile→Stable
- Heavy Insider Buying Conviction→Stable
- Strong Liquidity Cushion→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 11, 2026
Electra Therapeutics, Inc. (ETRA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.98: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality.
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart,... Read more
Sell if holding. Engine safety override at $8.98: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality. Chart setup: RSI 48 mid-range, Bollinger mid-band. Score 5.5/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Electra Therapeutics, Inc.
Latest news
- NEWS This FirstEnergy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday — benzinga Oct 26, 2026 neutral
- NEWS HC Wainwright & Co. Initiates Coverage On Electra Therapeutics with Buy Rating, Announces Price Target of $30 — benzinga Oct 26, 2026 positive
- NEWS 12 Health Care Stocks Moving In Friday's Pre-Market Session — benzinga Oct 23, 2026 neutral
- NEWS Star Therapeutics Announces $200M Private Financing To Support Its Pipeline Of Potential Best-in-Disease Therapies — benzinga Oct 23, 2026 neutral
- NEWS JP Morgan Initiates Coverage On Electra Therapeutics with Overweight Rating, Announces Price Target of $36 — benzinga Oct 22, 2026 positive
Generated 2026-10-29T11:08:51Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.98: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality. Chart setup: RSI 48 mid-range, Bollinger mid-band. Prior stop was $8.35. Score 5.5/10, moderate confidence.
Resistance target: $11.34 (+26.3% upside). Prior stop was $8.35. Stop-loss: $8.35.
DATA_ISSUE: analyst_target_implausible (raw $33.20 vs price $8.98 — ratio 3.7×). Rejected, falling back to technical TP.; Quality below floor (2.6 < 4.0).
Electra Therapeutics, Inc. trades at a P/E of N/A (forward -5.0). TrendMatrix value score: 5.0/10. Verdict: Sell.
What does Electra Therapeutics, Inc. do?Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets...
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.